Competitive
Projects

Competitive projects

We develop together with internationally renowned research groups, competitive projects of the most important national and international calls, such as those of the Ministry of Health, Ministry of Education, Instituto de Salud Carlos III, Ministry of Economy and Competitiveness (MINECO), IMI, COST, or H2020, among others.

On this page, you will find those still in force and active and those already completed. 

  • Current
  • Historical
COVIDRIVE logo
«COVID-19 Development of Robust and Innovative Vaccine Effectiveness», es un proyecto internacional cuyo objetivo principal es la estimación de la efectividad de las vacunas de la COVID-19 en Europa.
 

DRIVE – Development of Robust and Innovative Vaccine Effectiveness. Increasing understanding of influenza vaccine effectiveness in Europe.

DRIVE is a public-private partnership that promotes European cooperation in influenza vaccine effectiveness studies. It seeks to establish a network of sufficient size to obtain robust, high quality, and
specific brand name for all influenza vaccines used in the EU each season.


Go to project page

GIHSN AIV

FISABIO coordinated the Global Hospital Network for Influenza Surveillance,
called "Global Influenza Hospital Surveillance Network"; (GIHSN), from its creation by Sanofi Pasteur in 2012 until the 2016/2017 season.

Currently, it is made up of hospitals in Spain (located in the Valencian Community), Canada, Mexico, Peru, Argentina, Russia, Romania, Poland, the Czech Republic, France, Tunisia, the Ivory Coast, South Africa, Kazakhstan, Serbia, Kenya, India, and China. Since the 2017/2018 season, FISABIO has participated as a partner.


Go to project page

Project sponsored by the Innovative Medicines Initiative (IMI) aimed at redesigning clinical trials by developing a favourable framework to facilitate the implementation of Remote Decentralized Clinical Trials (RDCT) in Europe.

Go to project page
VITAL - Vaccines and Infectious Diseases in the Ageing Population sponsored by the Innovative Medicines Initiative (IMI). The objective of VITAL is to study the burden of infectious diseases in those over 50 years of age. For this, epidemiological studies will be carried out, including analyses of the socio-economic impact, as well as a Clinical Trial to analyze the response to vaccines in this population group.

Go to project page

WHO-GVS-MCC

Vaccine monitoring and data collection are very complex, especially for pregnant women. For this reason, it is necessary to obtain quality data, which is difficult to gather in developing countries because they lack the infrastructures to do so. With this idea in mind, the Global Vaccine Safety Collaborative Initiative (GVS-MCC) was created, in which a total of 25 centers in 8 countries in Europe, Africa, and Asia participate. The study focuses on developing standardized surveillance systems that will underpin current and future vaccination schedules for pregnant women.

VAHNSI-Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses. It is an active hospital surveillance network for the study of respiratory viruses in the Comunitat Valenciana (Spain). At the same time, it feeds other projects such as DRIVE, GIHSN, RSV GEN, or GISAID, creating a very powerful, data sharing infrastructure [Link infrastructure section].

Go to project page

Project funded by the Health Research Fund (FIS) designed by the Carlos III Health Institute (ISCIII) to estimate the efficacy against influenza and other acute respiratory infections in children between 12 and 35 months.

Go to the project page

El proyecto ACCESS pretende establecer una infraestructura europea para monitorizar las vacunas contra el COVID-19. ACCESS realizará estudios específicos y proporcionará información documentada sobre la factibilidad de abordar resultados de cobertura, seguridad y efectividad.

Go to project page 

«Estudio prospectivo de cohorte para la investigación de los resultados de salud maternos, de embarazo y neonatales para mujeres y neonatos infectados por SARS-CoV-2.»
 
El objetivo es analizar si la infección por SARS-CoV-2 en mujeres embarazadas aumenta el riesgo de efectos adversos. Además, se pretende estimar el riesgo de transmisión del virus de madre a hijo durante el embarazo, el parto y el post-parto (incluyendo el período de lactancia). 

Se espera que los resultados del estudio sirvan para desarrollar guías y recomendaciones, tanto para las madres como para los recién nacidos, en el contexto de seguridad durante la pandemia, caracterizando el curso y la progresión de la COVID-19 durante el embarazo.

Go to project page

The project of the "Europe Research 2019" Dynamization Actions call State Program of R+D+i Oriented to the Society Challenges of the Ministry of Science, Innovation, and Universities for the realization of the project proposal RIA-H2020 "Addressing Vaccine Hesitancy; new strategies to increase vaccination coverage in the Member States."

VACMA – Vaccine Media Analytics
One of the greatest achievements of medical science is the development of vaccines: they are more accessible, their prices are falling, the evidence of their positive effects is increasing, and side effects have reduced. Yet, there is a growing number of people who are choosing to reject them.

This project does not focus on that visible group of opponents, but on the less visible one, where the vaccine is added to their other daily problems. The project aims to identify and understand this group.

CAP-PRI

Community Adquired Pneumonia – Pediatric Research Initiative

Go to the project page
ENSURE- Enabling kNowledge Sustainability Usability and Recovery for Economic value. Ensuring long-term usability for the spiral of data produced or controlled by organizations with commercial interests is becoming a major issue. By leveraging use cases in healthcare, finance, and clinical trials, ENSURE will significantly expand digital preservation, which has focused on relatively homogeneous cultural heritage data to date.

Go to project page
Currently VAC4EU: ADVANCE- Accelerated Development of Vaccine benefit-risk Collaboration in Europe Project. ADVANCE is a project sponsored by the Innovative Medicines Initiative (IMI) to create an efficient and sustainable infrastructure for rapid and integrated risk-benefit monitoring of vaccines after approval. Including a code of conduct and governance principles for public-private collaborative studies.

Go to the project page

Go to The ACCESS project aims to establish a European infrastructure that is ready to monitor future vaccines against COVID-19. ACCESS will conduct specific studies and provide documented information on the feasibility of addressing coverage, safety, and effectiveness outcomes.

Proyecto i-CONSENT logo

Improving the guidelines for Informed Consent, including vulnerable populations under a gender perspective.

CONSENT is a European project financed by the EU Horizon 2020 program aimed at developing guidelines to improve the Informed Consent process in clinical trials. The project studies the implications of the gender perspective and vulnerable groups, making use of new technologies to present information.

Go to project page